June 1, 2026 · Form 4 insider transaction
PYOTT DAVID E I bought 3,830 shares of Alnylam Pharmaceuticals, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.